Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans.
Level 3 - non-randomized controlled study
Retrospective propensity score-matched cohort study
PubMed 34569707 · doi:10.1002/alz.12465
What was done
A propensity score-matched retrospective cohort study evaluated 40,207 patients with rheumatoid arthritis (RA) within the US Veterans Affairs health-care system between 2000 and 2020. Investigators matched 2,510 RA patients prescribed tumor necrosis factor (TNF) inhibitors 1:2 to RA control patients to assess the long-term risk of developing all-cause dementia and Alzheimer's disease (AD) over up to 20 years of follow-up.
What was found
TNF inhibitor treatment was associated with a 36% lower risk of all-cause dementia (hazard ratio [HR]: 0.64, 95% CI: 0.52–0.80), an association that remained consistent across 5 to 20 years after RA diagnosis. For Alzheimer's disease specifically, TNF inhibitor use was associated with a 43% lower risk over 20 years of follow-up (HR: 0.57, 95% CI: 0.39–0.83).
Why it matters
These findings suggest that systemic TNF inhibition in inflammatory disease may confer long-term neuroprotective benefits against neurodegenerative decline and Alzheimer's pathology.
Limits
The study is retrospective and observational, meaning residual confounding or channeling bias cannot be fully ruled out despite propensity matching. The US Veterans Affairs population is typically heavily male, potentially limiting generalizability. Specific drug classes, doses, adherence, and baseline cognitive status were not reported in the abstract.
Cited by
- supports Individuals taking TNF-alpha inhibitor drugs have approximately a 50% lower risk of developing Alzheimer's disease.